• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Nat Commun . Long-term monitoring of SARS-CoV-2 seroprevalence and variants in Ethiopia provides prediction for immunity and cross-immunity

tetano

Editor, Senior Moderator
Nat Commun


. 2024 Apr 24;15(1):3463.
doi: 10.1038/s41467-024-47556-2. Long-term monitoring of SARS-CoV-2 seroprevalence and variants in Ethiopia provides prediction for immunity and cross-immunity

Simon Merkt[SUP] #[/SUP][SUP] 1 [/SUP], Solomon Ali[SUP] #[/SUP][SUP] 2 [/SUP], Esayas Kebede Gudina[SUP] #[/SUP][SUP] 3 [/SUP], Wondimagegn Adissu[SUP] 3 [/SUP], Addisu Gize[SUP] 2 4 [/SUP], Maximilian Muenchhoff[SUP] 5 6 [/SUP], Alexander Graf[SUP] 7 [/SUP], Stefan Krebs[SUP] 7 [/SUP], Kira Elsbernd[SUP] 8 9 [/SUP], Rebecca Kisch[SUP] 8 [/SUP], Sisay Sirgu Betizazu[SUP] 2 [/SUP], Bereket Fantahun[SUP] 2 [/SUP], Delayehu Bekele[SUP] 2 [/SUP], Raquel Rubio-Acero[SUP] 8 [/SUP], Mulatu Gashaw[SUP] 3 [/SUP], Eyob Girma[SUP] 3 [/SUP], Daniel Yilma[SUP] 3 [/SUP], Ahmed Zeynudin[SUP] 3 [/SUP], Ivana Paunovic[SUP] 8 10 [/SUP], Michael Hoelscher[SUP] 6 8 10 11 [/SUP], Helmut Blum[SUP] 7 [/SUP], Jan Hasenauer[SUP] 12 13 14 [/SUP], Arne Kroidl[SUP] 15 16 [/SUP], Andreas Wieser[SUP] 17 18 19 20 [/SUP]



Affiliations
Abstract

Under-reporting of COVID-19 and the limited information about circulating SARS-CoV-2 variants remain major challenges for many African countries. We analyzed SARS-CoV-2 infection dynamics in Addis Ababa and Jimma, Ethiopia, focusing on reinfection, immunity, and vaccination effects. We conducted an antibody serology study spanning August 2020 to July 2022 with five rounds of data collection across a population of 4723, sequenced PCR-test positive samples, used available test positivity rates, and constructed two mathematical models integrating this data. A multivariant model explores variant dynamics identifying wildtype, alpha, delta, and omicron BA.4/5 as key variants in the study population, and cross-immunity between variants, revealing risk reductions between 24% and 69%. An antibody-level model predicts slow decay leading to sustained high antibody levels. Retrospectively, increased early vaccination might have substantially reduced infections during the delta and omicron waves in the considered group of individuals, though further vaccination now seems less impactful.


 
Back
Top Bottom